Loading
Every phase 2 or 3 drug trial that was recruiting, about to open or still running for triple-negative breast cancer on ClinicalTrials.gov in September 2026, with the hospitals in the United Kingdom that take part named where the registry lists them.
The ClinicalTrials.gov v2 API was searched on 24 September 2026 for interventional phase 2, 2/3 and 3 studies naming triple-negative breast cancer that were recruiting, not yet recruiting, enrolling by invitation or (for phase 3 and 2/3) active but closed to recruitment: 395 studies, of which 92 were already in the corpus and 18 are hand-written here. The 213 new registry-only records linked here carry the registry facts (title, sponsor, enrolment, dates, interventions, conditions, the triple-negative eligibility sentence and the countries) and no outcomes; trials with a HER2-positive or hormone-receptor-positive cohort alongside a triple-negative one are left out. Of the 213, 146 are phase 2, 32 phase 1/2, 31 phase 3 and 4 phase 2/3; 125 are recruiting, 75 not yet recruiting, 3 enrolling by invitation and 10 phase 3 or 2/3 trials active but closed. Most are run from China, the United States, France and Italy; the United Kingdom appears as a site in the hand-written UK trials (PARTNER at 30 hospitals, PHOENIX at 6, c-TRAK TN at 17, DIAMOND and BARBICAN at Barts, A-BRAVE at 8) and in the industry phase 3 trials ASCENT-03, ASCENT-04, ASCENT-05, TROPION-Breast02, 03, 04 and 05, CAPItello-290 and BEGONIA, whose UK sites are quoted on each record. The ISRCTN registry lists 41 hits for the same search, almost all dual-registered on ClinicalTrials.gov (DIAMOND is one), plus observational and imaging studies not carried here.
Shares A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer, A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC, Capecitabine in Low Risk Triple Negative Breast Cancer, HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry..
Shares Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TN, TIL-Driven De-escalated Chemotherapy in Stage I-II TNBC, QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer, Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer.
Shares A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC, Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer, QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride, The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breas.
Shares Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy, NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer, TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer, First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients..
Shares A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer, A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy fo, A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast, ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation.
Shares Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TN, TIL-Driven De-escalated Chemotherapy in Stage I-II TNBC, QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer, Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer.
Shares Capecitabine in Low Risk Triple Negative Breast Cancer, PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC, Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer, Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy.
Shares Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy, Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer, NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer, PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease.